Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04599504
PHASE2/PHASE3

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery. This is a controlled test of whether, amongst non-responders to acute treatments, lisdexamfetamine medication results in superior outcomes compared with placebo.

Official title: Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2022-01-02

Completion Date

2027-05

Last Updated

2026-02-04

Healthy Volunteers

No

Interventions

DRUG

Lisdexamfetamine Dimesylate (Medication)

Medication will be taken daily in pill form.

OTHER

Placebo

Placebo will be inactive and taken daily in pill form.

Locations (1)

Yale School of Medicine

New Haven, Connecticut, United States